Chiba University Researchers Link High Fcγ Receptor Affinity to Fatal Antibody Drug Anaphylaxis

Chiba University researchers identify Fcγ receptor binding as the key driver of fatal anaphylaxis in antibody therapies, offering a path to safer cancer drugs.

By: AXL Media

Published: Apr 8, 2026, 11:02 AM EDT

Source: Information for this report was sourced from Chiba University

Decoding the Mechanism of Antibody-Induced Allergic Shock

While antibody therapeutics have revolutionized cancer and inflammatory disease treatment, the risk of sudden, fatal anaphylaxis remains a persistent safety concern. New research led by Professor Hiroto Hatakeyama and Dr. Ruiheng Tang at Chiba University has pinpointed the interaction between these drugs and Fcγ receptors as a critical driver of this risk. Traditionally, anaphylaxis is attributed to the immunoglobulin E (IgE) pathway, but this study confirms the existence of a potent, IgE-independent pathway. The researchers found that when antibody drugs possess a high affinity for Fcγ receptors found on immune cells, they are captured more aggressively, leading the body to produce excessive antidrug antibodies (ADAs) that eventually trigger systemic shock.

The Role of Tumor-Associated Myeloid Cells in ADA Induction

The study utilized tumor-bearing mouse models to observe how specific immune cells interact with programmed death-ligand 1 (PD-L1) targeting antibodies. The team discovered that tumor-associated myeloid cells act as "gatekeepers" that capture high-affinity antibodies. Once captured, these antibodies are processed in a way that promotes heightened immune activation. In experiments where the 10F.9G2 antibody—which has a robust binding ability—was administered, 100% of the subjects developed fatal anaphylaxis. Conversely, antibodies with lower binding affinities, such as the MIH6 variant, showed negligible ADA production and no adverse allergic reactions, suggesting that the "capture" mechanism is the primary catalyst for the immune system's overreaction.

Validating the Fcγ Receptor Hypothesis Through Modification

To verify that the Fcγ receptor was the specific culprit, the Chiba University team engineered modified versions of the high-risk 10F.9G2 antibody with significantly reduced binding capabilities. These "silenced" versions failed to trigger anaphylaxis and resulted in dramatically lower ADA levels. This experimental success provides a clear roadmap for pharmaceutical developers: by "tuning" the affinity of the antibody's Fc region, it may be possible to maintain a drug's therapeutic efficacy while virtually eliminating the risk of life-threatening allergic responses. The study further noted that blocking these receptors entirely in the mouse models improved survival rates and l...